Pamplona

• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan … Recruiting
  2024-515280-60-00 5 2025-05-29 Lupus nephritis
• A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla … Recruiting
  2024-514341-10-00 1 2025-05-27 Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting
  2024-514937-39-00 5 2025-05-20 Dravet Syndrome
• Cetuximab With or Without Paclitaxel After Pembrolizumab-Chemotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. Recruiting
  2024-514953-31-00 4 2025-05-20 Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva … Recruiting
  2024-515984-68-00 4 2025-05-20 Non-small cell lung cancer (NSCLC)
• A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer Recruiting
  2024-516615-25-00 1 2025-05-14 hepatocellular carcinoma (HCC)
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b … Recruiting
  2024-519498-20-00 9 2025-05-13 Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Syndrome (MD
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs). Recruiting
  2024-511915-21-01 1 2025-05-05 advanced or metastasic triple-negative breast cancer
• Clinical trial for the use of a humanized CART directed against BCMA (ARI0002h) in patients with newly diagnosed primary plasma cell leukemi … Recruiting
  2024-515053-21-00 4 2025-04-30 Plasma cell leukaemia
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas … Recruiting
  2023-508112-35-00 4 2025-04-15 ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto … Recruiting
  2023-504180-16-00 5 2025-04-07 Advanced Breast Cancer
• A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i … Recruiting
  2023-507613-10-01 7 2025-03-31 Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE)
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Recruiting
  2024-516380-81-00 4 2025-02-28 Treatment of IgAN
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No … Recruiting
  2023-509806-31-00 4 2025-02-11 Non-Small Cell Lung Cancer
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Recruiting
  2024-513199-16-00 1 2025-02-04 Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo

Showing 241–264 of 821 trials